Document Type

Article

Publication Date

2017

Keywords

serotonin syndrome, ifosfamide neurotoxicity, methylene blue

Abstract

Methylene blue is a widely used treatment for ifosfamide neurotoxicity. We present a case of severe encephalopathy complicating ifosfamide-based therapy for recurrent retroperitoneal leiomyosarcoma. After treatment with methylene blue, the patient experienced clinical decompensation and was diagnosed with serotonin syndrome based on a constellation of clinical findings. Withdrawal of methylene blue and other serotonergic medications led to clinical stabilization and ultimately neurological recovery. Our case highlights the challenge of diagnosing serotonin syndrome in the face of preexisting ifosfamide neurotoxicity, as there is significant clinical overlap between these 2 syndromes. Practitioners must remain vigilant of this potential life-threatening complication in this vulnerable population.

Digital Object Identifier (DOI)

https://doi.org/10.1177/1073274817729070

Rights Information

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Citation / Publisher Attribution

Cancer Control, v. 24, issue 5, p. 1-4

Was this content written or created while at USF?

Yes

Included in

Neurology Commons

Share

COinS